Triferic’s Modified Indication Gets Past FDA Panel Despite Real World Applicability Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee endorses approval of Rockwell’s Triferic, but for only half of proposed indication; support tempered by “artificial” nature of Phase III studies, a claim to which Rockwell’s CMO agreed.